Back to top
more

Omnicell (OMCL)

(Real Time Quote from BATS)

$31.66 USD

31.66
63,910

+0.83 (2.69%)

Updated Aug 12, 2025 11:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 245)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJT

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Omnicell (OMCL)

by Zacks Equity Research

Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

CERN vs. OMCL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CERN vs. OMCL: Which Stock Is the Better Value Option?

Zacks Equity Research

Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SLYG

Zacks Equity Research

Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VIOG

Zacks Equity Research

Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.

Zacks Equity Research

Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPSM

Zacks Equity Research

Omnicell (OMCL) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

NEOGEN (NEOG) Inks Deal to Boost Global Genomics Business

by Zacks Equity Research

NEOGEN's (NEOG) latest acquisition of Genetic Veterinary Sciences, Inc. will bolster the global genomics business.

Zacks Equity Research

NextGen's (NXGN) Integrated Platform Gets Adopted by Monmouth

by Zacks Equity Research

NextGen's (NXGN) comprehensive solution suite was adopted by Monmouth to better cater to patients' medical and dental needs.

Zacks Equity Research

CERN vs. OMCL: Which Stock Is the Better Value Option?

by Zacks Equity Research

CERN vs. OMCL: Which Stock Is the Better Value Option?

Zacks Equity Research

Omnicell (OMCL) Down 1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

NEOGEN (NEOG) Strengthens Global Foothold With Delf Buyout

by Zacks Equity Research

NEOGEN (NEOG) management believes that Delf's 40 years of experience in the UK dairy hygiene market will help it strengthen its foothold in this region's dairy chemicals market.

Zacks Equity Research

Walgreens Boots (WBA) Faces Margin Pressure, Solvency Issue

by Zacks Equity Research

Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margin significantly.

Zacks Equity Research

Medtronic (MDT) Gets Health Canada License for GI Genius Module

by Zacks Equity Research

Medtronic Canada ULC, a subsidiary of Medtronic (MDT), receives Health Canada license for the GI Genius module that aids in colorectal cancer screening.

Zacks Equity Research

Here's Why You Should Invest In Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bruker's (BRKR) better-than-expected results and strong segmental performance.

Zacks Equity Research

QIAGEN (QGEN), DiaSorin to Broaden Access to Latent TB Testing

by Zacks Equity Research

QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.

Zacks Equity Research

Here's Why You Should Hold on to Globus Medical (GMED) for Now

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.

Zacks Equity Research

Here's Why You Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.

Zacks Equity Research

Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.

Zacks Equity Research

Smith+Nephew (SNN) Introduces Real Intelligence & CORI System

by Zacks Equity Research

Smith+Nephew (SNN) debuts new brand of enabling technology solutions as well as its next-generation handheld robotics platform in Canada.

Zacks Equity Research

Here's Why You Should Hold on to Integra (IART) Stock for Now

by Zacks Equity Research

Investors are optimistic about Integra (IART) given its better-than-expected results and robust performance of the CSS arm in the third quarter.

Zacks Equity Research

Allscripts' (MDRX) Services Leveraged by Next Level Urgent Care

by Zacks Equity Research

Allscripts' (MDRX) Touchworks platform and Microsoft Azure hosting & services will be implemented across all Next Level Urgent Care's sites in Houston.

Zacks Equity Research

Here's Why You Should Hold on to Syneos Health (SYNH) for Now

by Zacks Equity Research

Investors about optimistic about Syneos Health (SYNH) given its better-than-expected results as well as strong segmental performance during the third quarter.

Zacks Equity Research

3 Reasons Growth Investors Will Love Omnicell (OMCL)

by Zacks Equity Research

Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.